ANNX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 93722 min ago

@ $5.26

Išleistas: 14 vas. 2024 @ 21:48

Grąža: -13.23%

Ankstesnis signalas: vas. 14 - 16:31

Ankstesnis signalas: Pardavimas

Grąža: 2.24 %

Live Chart Being Loaded With Signals

Commentary (19 bal. 2024 @ 23:00):

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders...

Stats
Šios dienos apimtis	1.15M
Vidutinė apimtis	1.58M
Rinkos kapitalizacija	479.19M
EPS	$0 ( 2024-04-01 )
Kita pelno data	( $-0.440 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.58
ATR14	$0.0130 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Carson William H.	Buy	3 200	Common Stock
2024-02-16	Love Douglas	Buy	656 200	Stock Option (Right to Buy)
2024-02-16	Dananberg Jamie	Buy	160 000	Stock Option (Right to Buy)
2024-02-16	Dananberg Jamie	Buy	39 000	Common Stock
2024-02-16	Artis Dean Richard	Buy	160 000	Stock Option (Right to Buy)

INSIDER POWER
80.79
Last 94 transactions
Buy: 9 088 380 \| Sell: 879 119

Tūris Koreliacija

Ilgas: -0.15 (neutral)

Trumpas: -0.86 (strong negative)

Signal:(38.489) Neutral

Annexon, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
RMRM	0.934
GTHX	0.93
STKL	0.913
NUTX	0.91
EYE	0.91
DXCM	0.91
SDG	0.909
EAR	0.908
SVOK	0.907
RRGB	0.906

10 Labiausiai neigiamai susiję koreliacijos
HDSN	-0.916
LCA	-0.9
MDWT	-0.896
NVCN	-0.89
SENEA	-0.885
OHAA	-0.882
HNRG	-0.879
ROKU	-0.878
IGTA	-0.877
FCBP	-0.877

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Annexon, Inc. Koreliacija - Valiuta/Žaliavos

0.25
( neutral )

0.26
( neutral )

0.00
( neutral )

-0.10
( neutral )

Annexon, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-3.27M (0.00 %)
EPS:	$-1.770

Q4	2023
Pajamos:	$0
Bruto pelnas:	$-834 000 (0.00 %)
EPS:	$-0.360

Q3	2023
Pajamos:	$0
Bruto pelnas:	$-823 000 (0.00 %)
EPS:	$-0.430

Q2	2023
Pajamos:	$0
Bruto pelnas:	$-810 000 (0.00 %)
EPS:	$-0.470

Financial Reports:

No articles found.

Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.